Welcome to PharmInfoNet!
Sponsorship Options
Announcements
Contents

7 January 1998:
Focus On Thalidomide
Thalidomide
Gets
a Second
Chance
In the early 1960s the very mention of the word "thalidomide" was enough to conjure up the vision of a parent's worst nightmare: the birth of a deformed child. During that period, approximately 8,000 babies were born in Europe with severe defects after their mothers had taken thalidomide. Today, almost 40 years later, manufacturers are conducting clinical trials to see if thalidomide can treat inflammation common to a host of diseases, and combat weight loss and aphthous ulcers in AIDS patients. Other trials are studying thalidomide's effect on the eye disease macular degeneration; on breast, prostate and brain cancer; and on Kaposi's sarcoma (a form of cancer common in AIDS patients). And, the FDA has recently issued an approvable letter (final
procedural agreements with the manufacturer are in process) for the use of thalidomide in
the treatment of ENL (type II lepra reaction), which is a serious, severe complication of leprosy.
continued...
Also see:
MedWatch: FDA APPROVES ALLEGRA-D
PharmInfoNet has received dozens of awards and badges of distinction!
See what other people are saying about us. We think you will agree that PharmInfoNet
is one of the very best sources of health and drug information on the Internet.
Among the awards we have received are:
New additions ...
Webmaster's Report
Medical Sciences Bulletin
MedWatch News
CARDIO-CONSULT Archive
Pharmaceutical
Information Network
Advertising/Sponsorship Options
A service provided by
VirSci Corporation
Mission Statement |
Editorial Board |
Expert Panel |
Disclaimer
Webmaster
|